Amplo Biotechnology
Phase 1/2Amplo is developing gene therapies (AAV) for diseases affecting the neuromuscular junction (e.g. congenital myasthenia, ALS, ageing, myasthenia gravis)
Founded
2020
Focus
RNA & Gene TherapyViral Technology
About
Amplo is developing gene therapies (AAV) for diseases affecting the neuromuscular junction (e.g. congenital myasthenia, ALS, ageing, myasthenia gravis)
Funding History
1Total raised: $3.2M
Seed$3.2MUndisclosedFeb 15, 2023
Company Info
TypePrivate
Founded2020
LocationSan Diego, United States
StagePhase 1/2
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile